MAGIC Cell-5-Combicytokine Trial

Phase 3UnknownNCT00501917

Seoul National University Hospital116 enrolled

Overview

Combination use of darbepoetin and G-CSF will improve left ventricular systolic function in patients with acute myocardial infarction who receive intracoronary infusion of mobilized peripheral blood stem cell in comparison with patient who treated with conventional measures and who received intracoronary infusion of mobilized peripheral blood stem cell by G-CSF alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

116

Conditions

Acute Myocardial Infarction

Interventions

G-CSF with/without darbepoetin, peripheral blood stem cell infusionDRUG

Eligibility

Sex: ALLMin age: 15 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ST elevation acute myocardial infarction * \< 80years * successful revascularization of culprit vessel Exclusion Criteria: * uncontrolled congestive heart failure * uncontrolled myocardial ischemia * uncontrolled ventricular arrhythmia * malignancy * serious hematologic disease * chronic renal failure

Locations (1)

Seoul National Univesity Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

change of left ventricular ejection fraction measured by cardiac MRI

Time frame: 6, 12, and 24month

Secondary Outcomes

wall motion score index exercise capacity BNP

Time frame: 6,12, 24month

Central Contacts

Hyo-Soo Kim, MD PhD

CONTACT

82-2-2072-2226 hyosoo@snu.ac.kr

Hyun-Jae Kang, MD PhD

CONTACT

82-2-2072-2279 nowkang@snu.ac.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.